Methyl Linderone Suppresses TPA-Stimulated IL-8 and MMP-9 Expression Via the ERK/STAT3 Pathway in MCF-7 Breast Cancer Cells

Jae-Hwan Yoon¹, Thu-Huyen Pham¹, Jintak Lee¹, Jiyon Lee¹, Hyung-Won Ryu², Sei-Ryang Oh², Jae-Wook Oh³*, and Do-Young Yoon¹*

¹Department of Bioscience and Biotechnology, Research Institute of Bioactive-Metabolome Network; ²Department of Stem Cell and Regenerative Biotechnology, Konkuk University, Seoul 05029, Republic of Korea
²Natural Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology, Cheongju 28116, Republic of Korea

Introduction

Breast cancer is the second most prevalent cause of cancer mortality and the most common gynecological cancer worldwide [1, 2]. In 2018, there were approximately 2 million cases and 627,000 deaths and these numbers are predicted to increase yearly [3]. The breast cancer survival rate has risen recently because of improved diagnosis and treatment with a diverse range of anti-cancer agents. However, mortality rates remain high due to metastasis [4]. The metastatic process begins with cell invasion, which includes degradation of the extracellular matrix (ECM) and changes in cell adhesion, cell interactions, and inherent tissue structure [5]. The ECM is composed of collagen, elastin, and fibronectin, and it can be degraded by extracellular proteinases, such as matrix metalloproteinases (MMPs), which are metastasis-related factors in breast cancer [6, 7]. MMPs are a family of proteolytic enzymes consisting of zinc-dependent endopeptidases. They have been reported to be involved in rheumatoid arthritis and metastasis [8, 9]. The MMP family is divided into six subclasses: matrilysines (MMP-7 and -26), membrane-bound MMPs (MMP-14, -15, -16, -17, -24, and -25), stromalysines (MMP-3, -10, and -11), collagensases (MMP-1, -8, -13, and -18), gelatinases (MMP-2 and -9), and an unclassified group [10]. Among the various MMP groups, MMP-2 (gelatinase-A) and -9 (gelatinase-B) are the key enzymes associated with metastasis and invasion [11]. Therefore, suppressing MMP-9 expression is a potential approach to control malignant metastasis. Many stimulators,
such as tumor necrosis factor-α, fibroblast growth factor-2, and 12-O-tetradecanoylphorbol-13-acetate (TPA) can induce MMP-9 overexpression [12, 13]. Among a variety of stimuli, TPA, as a tumor promoter, has been reported to induce MMP-9 expression by upregulating transcription factors, such as activator protein-1 (AP-1), signal transducer and activator of transcription-3 (STAT3), and nuclear factor kappa B (NF-kB) [14, 15]. TPA has also been shown to activate IL-8 expression and this model is widely used to assess carcinogenesis pathways [16].

Methyl linderone (ML) was initially isolated from the dried fruits of Lindera erythrocarpa Makino (family Lauraceae) [17]. This plant is used as a traditional medicine and is reported to have digestive, anti-bacterial, and anti-inflammatory effects [18]. However, the anti-migratory and anti-invasive effects of ML have not yet been fully examined. In this study, we evaluated the anti-metastatic and anti-invasive effects of ML in in TPA-stimulated MCF-7 breast cancer cells.

Materials and Methods

Preparation of ML

Lindera erythrocarpa fruits were collected from Jeju Island, Korea, in October 2013. A voucher specimen (KRIC 000372) was deposited in the Herbarium of the Korea Research Institute of Bioscience and Biotechnology (Korea). The target compounds were isolated from dried fruits of L. erythrocarpa as previously described [19]. Detailed information on the isolation procedure can be found in the Supplementary Material. Briefly, the extracts (770.0 g, yield 15.4%) were fractionated on a silica gel column (10 × 90 cm, JEO prep 60, 40-63 μm) and eluted using hexane-ethyl acetate mixtures (20:1 → 15:1 → 10:1 → 8:1 → 6:1 → 4:1 → 2:1 → 1:1) to give 10 pooled fractions. In fraction 8, ML was purified and identified by nuclear magnetic resonance (NMR); ultraviolet-visible spectrophotometry (UV); mass spectrometry (MS); and MS/MS, using high-resolution MS spectral data (HRMS).

Reagents

The stock solution of ML (100 mM) in dimethyl sulfoxide was stored in the dark at 4°C and then diluted in Dulbecco’s modified Eagle’s medium (DMEM; Hyclone, USA) immediately before use. The CellTiter 96 AQueous One Solution Cell Proliferation Assay reagent (3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulphophenyl]-2H-tetrazolium [MTS]) was obtained from Promega (USA). NE-PER Nuclear and Cytoplasmic Extraction Reagents were supplied from Thermo Fisher Scientific (USA). RIPA buffer was obtained from DynaBio (Korea). The ERK inhibitor, PD98059, and antibodies specific for p-ERK, ERK, p-JNK, JNK, p-p38, NF-κB p65, c-Jun, c-Fos, STAT3, and PARP were purchased from Cell Signaling Technology (USA). The horseradish peroxidase-conjugated anti-rabbit IgG and anti-mouse IgG secondary antibodies were purchased from Millipore Sigma (USA). Antibodies specific for GAPDH, p38, and NF-κB were obtained from Santa Cruz Biotechnology (USA).

Cell Lines

The human breast adenocarcinoma cell line, MCF-7, was obtained from the American Type Culture Collection (USA). Cells were cultured in DMEM containing 10% (v/v) heat-inactivated fetal bovine serum (Millipore Sigma) at 37°C in an atmosphere of 5% CO₂.

Cell Viability Assays

Cell viability was assessed using an MTS assay, according to the manufacturer’s instructions. Cells (1 × 10⁵ cells/well) were seeded in 96-well plates and then treated with various concentrations of ML and TPA (50 nM) for 24 h. Absorbance was measured at 492 nm using a microplate reader (Apollo LB 9110; Berthold Technologies, Germany).

Cell Migration Assays

For migration assays, cells (6 × 10⁵ cells/ml) were seeded onto the upper chambers (Corning Inc., USA) in DMEM without serum and treated with ML for 2 h. To the lower chamber, 750 μl of TPA-treated serum-free DMEM (50 nM) was then added. After incubation for 24 h, non-migrated cells were removed from the chamber. Migrated cells were stained with a Diff-Quik Solution kit (Sysmex, Japan). The number of migrated cells was assessed using a microscope. Cells were then dissolved in 10% acetic acid (100 μl) and colorimetrically measured at 620 nm.

Cell Invasion Assays

For invasion assay, cells (6 × 10⁵ cells/ml) were seeded onto upper chambers coated with 20 μl of Matrigel in DMEM without serum and then treated with ML for 2 h. To the lower chamber, 750 μl of TPA-treated serum-free DMEM (50 nM) was then added. After incubation for 24 h, non-invading cells were removed from the chamber. Invading cells were stained with a Diff-Quik Solution kit and were quantified using a microscope. The cells were then dissolved in 10% acetic acid (100 μl) and colorimetrically measured at 620 nm.

Gelatin Zymography

For gelatin zymography, cells (1 × 10⁵ cells/well) were seeded in 12-well plates and incubated until fully grown. After an overnight incubation, cells were pretreated with ML for 2 h and then treated with TPA (50 nM) for 24 h. Forty microliters of culture supernatant was loaded on 10% SDS-polyacrylamide gels containing 0.1% gelatin. Gels were stained with InstantBlue (Millipore Sigma) for 1 h in the dark. Areas of gelatinolytic degradation were observed on the dark blue background.
Western Blotting Analysis

Cells were treated with various ML concentrations for 2 h and then with TPA for 24 h. They were then harvested and lysed in RIPA buffer containing a protease inhibitor cocktail (Roche Diagnostics, Germany). The nuclear and cytoplasmic components were fractionated using NE-PER Nuclear and Cytoplasmic Extraction Reagents, according to the manufacturer’s instructions. The protein content of the extracts was quantified using the Bradford assay (BioRad, USA). Cell lysates were separated by 10-15% SDS polyacrylamide gel electrophoresis. The proteins were then transferred onto polyvinylidene difluoride membranes (Millipore Sigma), which were blocked in 5% powdered skim milk, in Tris-buffered saline containing 0.1% Tween-20, for 1 h at RT. Membranes were then incubated overnight at 4°C with specific primary antibodies. After washing, the membranes were incubated with secondary antibodies for 1 h at room temperature. The results were visualized using a chemiluminescence detection kit (Advanstar, USA).

qRT-PCR

Cells were incubated for 24 h and then treated with various concentrations of ML for 2 h and with TPA (50 nM) for 24 h. Cells treated with ML were harvested and RNA was extracted using an easy-BLUE Total RNA Extraction Kit (Intron Biotechnology, Korea), according to the manufacturer’s instructions. cDNA was reverse transcribed from the RNA samples using M-MuLV reverse transcriptase (New England Biolabs, USA). qPCR was evaluated using the SensiFAST SYBR NO-ROX Kit (Bioline, UK) and a Rotor-Gene 6000 series thermal cycler (software v1.7; Qiagen, Germany). Each sample contained one of the following primer sets: MMP-9, 5'- AATCTCACC GACAGGCAGCT-3' (forward), 5'- CCAAACTGGATGACGTGTC-3' (reverse); IL-8, 5'- CTTGGCACCTTCTCAGTATT-3' (forward), 5'- CTGAGCCCCCT TTCAAACT-3' (reverse); or GAPDH, 5'- TGATGACATCAAGAAGTGTTG-3' (forward), 5'- TCCTTGGAGGCC TGTTGCCC-3' (reverse).

Statistical Analysis

Data are presented as means ± SD (n = 3). One-way analysis of variance, followed by Tukey’s HSD test, were used to evaluate differences between groups. Values of p < 0.05 or < 0.01 were considered statistically significant.

Results

Effects of ML on MCF-7 Cell Viability

The non-cytotoxicity of ML on MCF-7 cells was assessed using an MTS assay, in the presence or absence of TPA (50 nM) for 24 h. The results showed that ML did not affect the viability of MCF-7 cells up to a concentration of 10 µM (Fig. 1). Therefore, non-cytotoxic concentrations of ML up to 10 µM were used in subsequent experiments, to study its anti-invasive and anti-migratory effects.

Effects of ML on the Invasion and Migration of TPA-Stimulated MCF-7 Cells

To evaluate whether ML had anti-metastatic properties, MCF-7 cells were pre-treated with ML for 2 h and then with TPA for 24 h. Invasion and migration rates were then assessed using Matrigel invasion and migration assays. As shown in Fig. 2, TPA-stimulated cell migration was inhibited by ML in a dose-dependent manner. Moreover, ML attenuated the invasion of TPA-stimulated MCF-7 cells (Fig. 2).

Effect of ML on MMP-9 Expression in TPA-Stimulated MCF-7 Cells

To elucidate whether ML could inhibit TPA-stimulated MMP-9 and IL-8 expression in MCF-7 cells, their mRNA expression levels were assessed by qRT-PCR. MMP-9 and IL-8 mRNA levels decreased with ML treatment, in a dose-dependent manner (Fig. 3). Moreover, the zymography

![Fig. 1. Chemical structure and cytotoxic effect of methyl linderone on TPA-stimulated MCF-7 cells.](image-url)
results indicated that the enzymatic activity of MMP-9, which was induced by TPA treatment, was suppressed by ML in MCF-7 cells. As shown in Fig. 3, these results demonstrated that ML inhibited the enzymatic activity of MMP-9 and MMP-9 and IL-8 mRNA expression levels under TPA-stimulated conditions in MCF-7 cells.

Effect of ML on ERK/MAPK in TPA-Stimulated MCF-7 Cells

Next, we assessed whether ML could affect MAPK signaling pathway factors, including ERK, JNK, and p38, which are involved in the regulation of the metastasis-related factors, IL-8 and MMP-9. TPA treatment was found to increase the phosphorylation of p-38, JNK, and ERK (Fig. 4). Only the phosphorylation of ERK was inhibited by ML in a dose-dependent manner, while the phosphorylation of JNK and p38 were not affected by ML (Fig. 4). Thus, TPA-stimulated phosphorylation of ERK was the target of ML in MCF-7 cells.

Effects of ML on Nuclear Translocation of Transcription Factors

The expression of metastasis-related factors is affected by specific transcription factors. Therefore, to examine the effect of ML on the translocation of transcription factors, nuclear fractionation experiments were performed. The nuclear translocation of AP-1 (including c-Jun and c-Fos subunits) and STAT3 was found to be suppressed by ML in TPA-treated MCF7 cells (Fig. 5). The ERK inhibitor, PD98059, was used to confirm that ERK was the upstream regulator of STAT3 and AP-1 in the ML-triggered signaling pathway. ML was found to have similar inhibitory effects of JNK and p38 were not affected by ML (Fig. 4). Thus, TPA-stimulated phosphorylation of ERK was the target of ML in MCF-7 cells.

**Fig. 2.** Effects of ML on breast cancer cell migration and invasion.

For migration assays, MCF-7 cells, without Matrigel, were pretreated with ML at the indicated concentrations and then treated with TPA (50 nM). For invasion assays, cells, with Matrigel, were treated with ML and TPA (50 nM). Results represent the mean ± SD of three experiments (TPA alone vs. TPA plus ML, *p < 0.05, **p < 0.01).
Methyl Linderone Suppresses Breast Cancer Metastasis

A 2019
Vol. 29
No. 0

as PD98059, on the TPA-stimulated nuclear translocation of AP-1 and STAT3 (Fig. 6A). Furthermore, IL-8 and MMP-9 mRNA expression was inhibited in cells pre-treated with PD98059 or ML, prior to TPA-treatment (Fig. 6B). These data showed that ML attenuated MMP-9 and IL-8 expression by suppressing the ERK signaling pathway.

Discussion

ML has been reported to regulate inflammation by suppressing nitric oxide synthesis, a mediator of acute inflammation, and to suppress the proliferation of H-ras-transformed rat-2 cells [17, 20]. However, the regulatory effects of ML on metastasis have not yet been fully demonstrated in human breast cancer. Therefore, we sought to evaluate in the current study whether ML could modulate the metastasis-related factors, IL-8 and MMP-9, to regulate the migration and invasion of breast cancer cells. Furthermore, the underlying mechanism by which ML may act in TPA-stimulated MCF-7 cells was investigated.

Metastasis is the leading cause of cancer-related mortality and it occurs frequently in breast cancer [21]. Tumor metastasis is complex and involves multiple processes, including ECM proteolytic degradation, cell invasion, and cell migration, resulting in cancer growth at the metastatic site [10]. MMP-9 is an important component of the basement membrane and has important functions in tissue recovery. However it can also support the metastatic features of cancer cells, helping them become motile and invasive [22, 23]. Previous studies have demonstrated the expression and activity of MMP-9 in a variety of human cancer cells, including breast cancer cells [23, 24]. Thus, targeting MMP-9 expression is a potential strategy to regulate tumor metastasis. In the present study, the TPA-stimulated migration and invasion of MCF-7 cells were inhibited by ML, via the suppression of MMP-9 expression and activity. IL-8, known as neutrophil chemoattractic factor, also plays a key role in metastasis and is reported to be overexpressed in breast cancer cells after TPA treatment [16]. In the present study, ML was found to inhibit IL-8 expression in TPA-stimulated MCF-7 cells. These results confirmed that ML has potential anti-metastasis effects by
Fig. 5. Effect of ML on transcription factors in TPA-stimulated MCF-7 cells. MCF-7 cells were pretreated with ML for 2 h and then treated with TPA. After 24 h of incubation, AP-1 and STAT3 levels were evaluated in nuclear and cytosolic fractions. The translocation of these factors was detected using specific antibodies. PARP and GAPDH were used as internal controls.

Fig. 6. Effect of ML on the metastasis-related factor, ERK. MCF-7 cells were pretreated with ML in the presence or absence of the ERK inhibitor, PD98059 (50 µM), for 2 h. After incubation, cells were treated with TPA for 24 h. Nuclear transcription factors were assessed by nuclear fractionation and western blotting (A). IL-8 and MMP-9 mRNA expression levels were evaluated by qRT-PCR (B). p-ERK levels were evaluated by western blotting (C). Results represent the mean ± SD of three experiments (TPA alone vs. TPA plus ML or PD98059, **p < 0.01; TPA plus ML vs. TPA plus ML and PD98059, # p < 0.05; TPA plus PD98059 vs. TPA plus ML and PD98059, $ p < 0.05).
reducing MMP-9 and IL-8 levels.

To assess the detailed mechanism underlying the anti-metastatic effects of ML, various transcription factors were investigated, including AP-1, STAT3, and NF-kB, which are known to be modulators of IL-8 and MMP-9 transcription [14, 25]. The TPA-stimulated nuclear translocation of AP-1 and STAT3 was attenuated by ML, suggesting that AP-1 and STAT3 are the main transcription factors involved in the signaling pathway regulated by ML. Moreover, MMP-9 and IL-8 expression has been reported to be modulated by the MAPK family (including ERK, JNK, and p38) via the signaling pathway regulated by ML. Moreover, MMP-9 and STAT3 are the main transcription factors involved in cancer invasion and migration. Therefore, the MAPK family (including ERK, JNK, and p38) via the signaling pathway regulated by ML. Moreover, MMP-9 and IL-8 expression has been reported to be modulated by the MAPK family (including ERK, JNK, and p38) via the signaling pathway regulated by ML. Moreover, MMP-9 and STAT3 are the main transcription factors involved in cancer invasion and migration.

In conclusion, ML significantly downregulated MMP-9 and IL-8 expression in TPA-stimulated MCF7 cells, by inhibiting the ERK/STAT3/AP-1-mediated signaling pathway. These results suggested that ML is a potential pharmacological agent for breast cancer treatment, to block cancer invasion and migration.

Acknowledgments

This paper was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean Government (2018R1A2B2001225) and partially the Konkuk University Researcher Fund in 2019.

Conflict of Interest

The authors have no financial conflicts of interest to declare.

REFERENCES